Secuado is a drug owned by Hisamitsu Pharmaceutical Co Inc. It is protected by 6 US drug patents filed from 2019 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 22, 2033. Details of Secuado's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11813364 | Patch |
Sep, 2033
(8 years from now) | Active |
| US10814002 | Patch and method for producing the same |
Jul, 2033
(8 years from now) | Active |
| US11123305 | Patch |
Jul, 2033
(8 years from now) | Active |
| US10022445 | Patch |
Jul, 2033
(8 years from now) | Active |
| US9687474 | Patch |
Jul, 2033
(8 years from now) | Active |
| US10583121 | Patch |
Jul, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Secuado's patents.
Latest Legal Activities on Secuado's Patents
Given below is the list of recent legal activities going on the following patents of Secuado.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Apr, 2024 | US10814002 |
| Recordation of Patent Grant Mailed Critical | 14 Nov, 2023 | US11813364 |
| Recordation of Patent eGrant | 14 Nov, 2023 | US11813364 |
| Email Notification Critical | 14 Nov, 2023 | US11813364 |
| Patent Issue Date Used in PTA Calculation Critical | 14 Nov, 2023 | US11813364 |
| Mail Patent eGrant Notification | 14 Nov, 2023 | US11813364 |
| Patent eGrant Notification | 14 Nov, 2023 | US11813364 |
| Email Notification Critical | 27 Oct, 2023 | US11813364 |
| Issue Notification Mailed Critical | 25 Oct, 2023 | US11813364 |
| Dispatch to FDC | 11 Oct, 2023 | US11813364 |
FDA has granted several exclusivities to Secuado. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Secuado, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Secuado.
Exclusivity Information
Secuado holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Secuado's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2022 |
US patents provide insights into the exclusivity only within the United States, but Secuado is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Secuado's family patents as well as insights into ongoing legal events on those patents.
Secuado's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Secuado's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 22, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Secuado Generics:
There are no approved generic versions for Secuado as of now.
Alternative Brands for Secuado
Secuado which is used for treating adults with schizophrenia by administering asenapine via a transdermal patch., has several other brand drugs using the same active ingredient (Asenapine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Allergan |
|
About Secuado
Secuado is a drug owned by Hisamitsu Pharmaceutical Co Inc. It is used for treating adults with schizophrenia by administering asenapine via a transdermal patch. Secuado uses Asenapine as an active ingredient. Secuado was launched by Hisamitsu in 2019.
Approval Date:
Secuado was approved by FDA for market use on 11 October, 2019.
Active Ingredient:
Secuado uses Asenapine as the active ingredient. Check out other Drugs and Companies using Asenapine ingredient
Treatment:
Secuado is used for treating adults with schizophrenia by administering asenapine via a transdermal patch.
Dosage:
Secuado is available in system form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.8MG/24HR | SYSTEM | Prescription | TRANSDERMAL |
| 5.7MG/24HR | SYSTEM | Prescription | TRANSDERMAL |
| 7.6MG/24HR | SYSTEM | Prescription | TRANSDERMAL |